188 related articles for article (PubMed ID: 23885889)
1. Urinary metabotyping of bladder cancer using two-dimensional gas chromatography time-of-flight mass spectrometry.
Pasikanti KK; Esuvaranathan K; Hong Y; Ho PC; Mahendran R; Raman Nee Mani L; Chiong E; Chan EC
J Proteome Res; 2013 Sep; 12(9):3865-73. PubMed ID: 23885889
[TBL] [Abstract][Full Text] [Related]
2. Noninvasive urinary metabonomic diagnosis of human bladder cancer.
Pasikanti KK; Esuvaranathan K; Ho PC; Mahendran R; Kamaraj R; Wu QH; Chiong E; Chan EC
J Proteome Res; 2010 Jun; 9(6):2988-95. PubMed ID: 20337499
[TBL] [Abstract][Full Text] [Related]
3. Low- and high-grade bladder cancer determination via human serum-based metabolomics approach.
Bansal N; Gupta A; Mitash N; Shakya PS; Mandhani A; Mahdi AA; Sankhwar SN; Mandal SK
J Proteome Res; 2013 Dec; 12(12):5839-50. PubMed ID: 24219689
[TBL] [Abstract][Full Text] [Related]
4. Metabolic footprinting of tumorigenic and nontumorigenic uroepithelial cells using two-dimensional gas chromatography time-of-flight mass spectrometry.
Pasikanti KK; Norasmara J; Cai S; Mahendran R; Esuvaranathan K; Ho PC; Chan EC
Anal Bioanal Chem; 2010 Oct; 398(3):1285-93. PubMed ID: 20686754
[TBL] [Abstract][Full Text] [Related]
5. Detection of bladder cancer in human urine by metabolomic profiling using high performance liquid chromatography/mass spectrometry.
Issaq HJ; Nativ O; Waybright T; Luke B; Veenstra TD; Issaq EJ; Kravstov A; Mullerad M
J Urol; 2008 Jun; 179(6):2422-6. PubMed ID: 18433783
[TBL] [Abstract][Full Text] [Related]
6. Discovery and validation of potential urinary biomarkers for bladder cancer diagnosis using a pseudotargeted GC-MS metabolomics method.
Zhou Y; Song R; Ma C; Zhou L; Liu X; Yin P; Zhang Z; Sun Y; Xu C; Lu X; Xu G
Oncotarget; 2017 Mar; 8(13):20719-20728. PubMed ID: 28157703
[TBL] [Abstract][Full Text] [Related]
7. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
8. Validation study of urinary metabolites as potential biomarkers for prostate cancer detection.
Gamagedara S; Kaczmarek AT; Jiang Y; Cheng X; Rupasinghe M; Ma Y
Bioanalysis; 2012 Jun; 4(10):1175-83. PubMed ID: 22651561
[TBL] [Abstract][Full Text] [Related]
9. [Bladder cancer biomarkers].
Dobrowolska-Glazar B; Glazar W; Dobrowolski Z; Lipczyński W
Przegl Lek; 2010; 67(7):479-83. PubMed ID: 21387760
[TBL] [Abstract][Full Text] [Related]
10. Distinct urinary metabolic profile of human colorectal cancer.
Cheng Y; Xie G; Chen T; Qiu Y; Zou X; Zheng M; Tan B; Feng B; Dong T; He P; Zhao L; Zhao A; Xu LX; Zhang Y; Jia W
J Proteome Res; 2012 Feb; 11(2):1354-63. PubMed ID: 22148915
[TBL] [Abstract][Full Text] [Related]
11. Nuclear matrix protein 22 for bladder cancer detection: comparative analysis of the BladderChek® and ELISA.
Hatzichristodoulou G; Kübler H; Schwaibold H; Wagenpfeil S; Eibauer C; Hofer C; Gschwend J; Treiber U
Anticancer Res; 2012 Nov; 32(11):5093-7. PubMed ID: 23155286
[TBL] [Abstract][Full Text] [Related]
12. Feasibility study of screening for bladder cancer with urinary molecular markers (the BLU-P project).
Roobol MJ; Bangma CH; el Bouazzaoui S; Franken-Raab CG; Zwarthoff EC
Urol Oncol; 2010; 28(6):686-90. PubMed ID: 21062653
[TBL] [Abstract][Full Text] [Related]
13. Nuclear matrix protein-22: a prospective evaluation in a population at risk for bladder cancer. Results from the UroScreen study.
Huber S; Schwentner C; Taeger D; Pesch B; Nasterlack M; Leng G; Mayer T; Gawrych K; Bonberg N; Pelster M; Johnen G; Bontrup H; Wellhäusser H; Bierfreund HG; Wiens C; Bayer C; Eberle F; Scheuermann B; Kluckert M; Feil G; Brüning T; Stenzl A;
BJU Int; 2012 Sep; 110(5):699-708. PubMed ID: 22313585
[TBL] [Abstract][Full Text] [Related]
14. Discovery of Apo-A1 as a potential bladder cancer biomarker by urine proteomics and analysis.
Li C; Li H; Zhang T; Li J; Liu L; Chang J
Biochem Biophys Res Commun; 2014 Apr; 446(4):1047-52. PubMed ID: 24661883
[TBL] [Abstract][Full Text] [Related]
15. Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study.
Pfister C; Chautard D; Devonec M; Perrin P; Chopin D; Rischmann P; Bouchot O; Beurton D; Coulange C; Rambeaud JJ
J Urol; 2003 Mar; 169(3):921-4. PubMed ID: 12576813
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of two new urinary tumor markers: bladder tumor fibronectin and cytokeratin 18 for the diagnosis of bladder cancer.
Sánchez-Carbayo M; Urrutia M; González de Buitrago JM; Navajo JA
Clin Cancer Res; 2000 Sep; 6(9):3585-94. PubMed ID: 10999749
[TBL] [Abstract][Full Text] [Related]
17. Searching for urine biomarkers of bladder cancer recurrence using a liquid chromatography-mass spectrometry and capillary electrophoresis-mass spectrometry metabolomics approach.
Alberice JV; Amaral AF; Armitage EG; Lorente JA; Algaba F; Carrilho E; Márquez M; García A; Malats N; Barbas C
J Chromatogr A; 2013 Nov; 1318():163-70. PubMed ID: 24139504
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis of bladder cancer and prediction of survival by urinary metabolomics.
Jin X; Yun SJ; Jeong P; Kim IY; Kim WJ; Park S
Oncotarget; 2014 Mar; 5(6):1635-45. PubMed ID: 24721970
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma.
Nisman B; Barak V; Shapiro A; Golijanin D; Peretz T; Pode D
Cancer; 2002 Jun; 94(11):2914-22. PubMed ID: 12115379
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the sensitivity and specificity of urine cytology, urinary nuclear matrix protein-22 and multitarget fluorescence in situ hybridization assay in the detection of bladder cancer.
Kehinde EO; Al-Mulla F; Kapila K; Anim JT
Scand J Urol Nephrol; 2011 Mar; 45(2):113-21. PubMed ID: 21091091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
